Irritable Bowel Syndrome - Pipeline Insight, 2025

This “Irritable Bowel Syndrome - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Irritable Bowel Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Irritable Bowel Syndrome: Understanding

Irritable Bowel Syndrome: Overview

Irritable Bowel Syndrome (IBS) is a chronic gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits, which can include diarrhea, constipation, or a mix of both. The exact cause of IBS is not well understood, but it is believed to involve a combination of factors such as abnormal gut motility, heightened sensitivity to pain, changes in the gut-brain interaction, and imbalances in the gut microbiota. Triggers for IBS symptoms can vary widely, including certain foods, stress, and hormonal changes. While there is no cure, treatment focuses on symptom management through dietary adjustments, medications, and lifestyle changes.

The signs and symptoms of Irritable Bowel Syndrome (IBS) typically include recurrent abdominal pain or discomfort, often accompanied by bloating and changes in bowel habits. These changes may manifest as diarrhea, constipation, or alternating episodes of both. Other common symptoms include excessive gas, mucus in the stool, and a feeling of incomplete bowel movements. Symptoms can vary in severity from person to person and may be triggered by factors such as certain foods, stress, or hormonal fluctuations.

The diagnosis of Irritable Bowel Syndrome (IBS) is primarily based on clinical symptoms, as there is no specific test for the condition. Physicians use the Rome IV criteria, which require that a patient experience recurrent abdominal pain at least one day per week for the past three months, associated with two or more of the following: pain related to bowel movements, changes in stool frequency, or changes in stool form. To rule out other conditions with similar symptoms, such as inflammatory bowel disease or celiac disease, physicians may conduct blood tests, stool tests, and sometimes colonoscopy.

The treatment of Irritable Bowel Syndrome (IBS) focuses on managing symptoms, as there is no definitive cure. Treatment is often tailored to the individual’s predominant symptoms, such as diarrhea, constipation, or abdominal pain. Dietary modifications, including increasing fiber intake, avoiding trigger foods like caffeine and certain carbohydrates, and following a low FODMAP diet, can help alleviate symptoms. Medications may be prescribed, such as antispasmodics for pain, laxatives for constipation, or antidiarrheal drugs. In some cases, antidepressants are used to reduce pain sensitivity and improve gut-brain interactions. Additionally, stress management techniques, such as cognitive behavioral therapy (CBT) or relaxation exercises, can play an important role in symptom control.

'Irritable Bowel Syndrome- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Irritable Bowel Syndrome pipeline landscape is provided which includes the disease overview and Irritable Bowel Syndrome treatment guidelines. The assessment part of the report embraces, in depth Irritable Bowel Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Irritable Bowel Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Irritable Bowel Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Irritable Bowel Syndrome.

Irritable Bowel Syndrome Emerging Drugs Chapters

This segment of the Irritable Bowel Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Irritable Bowel Syndrome Emerging Drugs

CIN-103: CinRx Pharma

CIN-103 is a novel formulation of phloroglucinol - a non-opioid based, small molecule approved in select countries for the treatment of GI disorders. Designed for long-term use, CinRx’s non-clinical & early development team deployed immediate-release and delayed-release processes to formulate a proprietary, pulsatile release delivery offering sustained drug exposures with less frequent dosing. CIN-103 is believed to target multiple IBS-D action points, including motility, secretion, pain, spasms and inflammation. Currently, the drug is in the Phase II stage of its development for the treatment of Irritable Bowel Syndrome.

RQ-00310941: RaQualia Pharma

RQ-00310941 is a novel 5-HT2B receptor antagonist developed by RaQualia Pharma, primarily targeting diarrhea-predominant irritable bowel syndrome (D-IBS). The 5-HT2B receptor is a subtype of serotonin receptors that plays a significant role in various physiological processes, including gastrointestinal motility. By antagonizing this receptor, RQ-00310941 aims to alleviate visceral hypersensitivity and abnormal defecation patterns observed in patients with IBS. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Irritable Bowel Syndrome.

BMC426: Biomica

BMC426 is a candidate therapeutic developed by Biomica, focused on treating irritable bowel syndrome (IBS). It is part of a consortium of live bacterial strains designed to address the symptoms associated with IBS, particularly visceral pain, which is a significant concern for patients suffering from this chronic digestive disorder. Currently, the drug is in the Preclinical stage of development to treat Irritable Bowel Syndrome.

Irritable Bowel Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Irritable Bowel Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Irritable Bowel Syndrome

• There are approx. 20+ key companies which are developing the therapies for Irritable Bowel Syndrome. The companies which have their Irritable Bowel Syndrome drug candidates in the most advanced stage, i.e. Phase II include, CinRx Pharma.

Phases

The report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Irritable Bowel Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Irritable Bowel Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Irritable Bowel Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Irritable Bowel Syndrome drugs.

Irritable Bowel Syndrome Report Insights

• Irritable Bowel Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Irritable Bowel Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Irritable Bowel Syndrome drugs?
• How many Irritable Bowel Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Irritable Bowel Syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Irritable Bowel Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Irritable Bowel Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Tryp Therapeutics
• CinRx Pharma
• Otsuka Pharmaceutical
• RaQualia Pharma
• Biomica

Key Products

• TRP-8802
• CIN-103
• OPS 2071
• RQ-00310941
• BMC426

This product will be delivered within 1-3 business days.